All In Biotech

Drug Trial Radar · NCT02836574

A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease

A Phase 2 Prospective, Randomized, Double-Arm, Deferred Treatment, Open Label, Repeat Dose, Safety and Efficacy Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 2 Diabetes and Chronic Kidney Disease

Last checked: Nov 20, 2026Latest source record: Aug 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

83

Actual

Start

Sep 2016

Primary completion

Dec 2023

Study completion Dec 2023

Sponsor

Lead sponsor
ProkidneyIndustry
Sponsor type
Industry
Collaborators
CTI Clinical Trial and Consulting Services
First posted
Jul 19, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the safety and efficacy of up to two REACT injections given 6 months (+4 weeks) apart and delivered into the biopsied kidney using a percutaneous approach in participants with Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD).

Conditions

  • Type 2 Diabetes Mellitus
  • Chronic Kidney Disease

Interventions

  • Renal Autologous Cell Therapy (REACT)Biological

    Autologous selected renal cells (SRC).

  • Renal BiopsyProcedure

    a procedure in which a small sample of kidney tissue is removed

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Renal FunctionTime frame: Through 24 months following last REACT injection for active arm and at least 12 months following last REACT injection for the deferred arm

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • University of Arizona

    Tucson, Arizona

  • Kidney Associates of Colorado

    Denver, Colorado

  • Yale Univeristy

    New Haven, Connecticut

  • University of Florida

    Gainesville, Florida

  • Boise Kidney and Hypertension Institute

    Meridian, Idaho

  • University of Chicago Medical Center

    Chicago, Illinois

  • University of Louisville

    Louisville, Kentucky

  • Renal Associates of Baton Rouge

    Baton Rouge, Louisiana

  • University of Michigan

    Ann Arbor, Michigan

  • Paragon Health

    Kalamazoo, Michigan

  • Nephrology & Hypertension Associates

    Tupelo, Mississippi

  • Mt. Sinai Hospital

    New York, New York

  • University of North Carolina- Chapel Hill

    Chapel Hill, North Carolina

  • Lehigh Valley Health Network

    Allentown, Pennsylvania

  • Vanderbilt University

    Nashville, Tennessee

  • University of Wisconsin-Madison

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.